ClinicalTrials.gg
RecruitingNCT05765175RADIATE-VTUpdated Oct 30, 2026

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

An interventional study of Varian Cardiac Radioablation (CRA) and Catheter Ablation (CA) in Tachycardia, Ventricular, sponsored by Varian, a Siemens Healthineers Company. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Varian, a Siemens Healthineers Company (part of Siemens Healthineers) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Oct 30, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Tachycardia, Ventricular with a site in United States — 34 open to participants now, 40 under way, 2 of them phase 3. Tachycardia, Ventricular · United States.

Planned enrollment
14th of 107
380 · median 60
Started
2023
with 11 others
No phase
68 of 154
18 open now
Primary completion
2028-10
later than 30 of 39 live
Registered
130th of 154
by date

Among the 154 studies in Tachycardia, Ventricular with a site in United States, this one is the 14th largest by planned enrollment of the 107 interventional ones that give a count, is one of 12 that started in 2023, is one of 68 with no phase, reaches primary completion later than 30 of the 39 other live ones, and was the 130th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

34 of the 154 studies in Tachycardia, Ventricular with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Tachycardia, Ventricular with a site in United States, or all of them as a file.
02

Study summary

RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.

03

Conditions studied

  • Tachycardia, Ventricular

Keywords

  • Cardiac radioablation
  • Ventricular tachycardia
  • Catheter ablation
  • Refractory ventricular tachycardia
  • High risk
  • SBRT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. High-risk VT, defined as:

    1. Ischemic and/or nonischemic cardiomyopathy, and
    2. Recurrent sustained monomorphic VT, defined as at least one of the following below, documented by ICD interrogation or in the prior 6 months, and having occurred after the last VT ablation:

      A: ≥3 episodes of monomorphic VT treated with anti-tachycardia pacing (ATP) at least one of which is symptomatic

      B: ≥1 appropriate ICD shock

      C: ≥3 episodes of sustained monomorphic VT within 24 hours treated with ICD shock or ATP

      D: sustained monomorphic VT below detection rate of ICD documented by ECG, and

    3. (LVEF) ≤49% and
    4. Previously underwent at least one standard of care CA for VT.
  2. Presence of a clinical indication for a repeat CA procedure for scar-mediated VT in the judgement of the treating investigator.
  3. Has failed amiodarone therapy or is intolerant to amiodarone:

    • Failed amiodarone therapy is defined as: appropriate ICD therapy or sustained monomorphic VT having occurred while the patient was taking amiodarone (minimum cumulative dose of 10 g).
    • Intolerant to amiodarone is defined as: previously tried or taken amiodarone but stopped due to medication related side effects or toxicities.
  4. Deemed to be medically and technically a candidate for further CA by the electrophysiologist investigator.
  5. Presence of an ICD.
  6. At least 18 years of age (or meets local age of majority).
  7. Ability to understand and willingness to sign an IRB approved written document.

Exclusion criteria

Exclusion Criteria:

  1. to a CA procedure for VT (e.g., presence of mobile LV thrombus, active systemic infection, active ischemic or other reversible causes of VT).
  2. Patients with expected, right ventricular scar only.
  3. Any prior radiation to the thorax region of the body.
  4. Known medical conditions associated with higher risk of radiotherapy complications in the judgement of the radiation oncologist (i.e., active connective tissue disorders, interstitial lung disease, etc.) that would preclude safe delivery of CRA.
  5. Current use of inotropes.
  6. Presence of a left-ventricular assist device (LVAD).
  7. Scheduled for LVAD or heart transplant procedures.
  8. Presence of a systemic illness likely to limit survival to \< 1 year.
  9. VT ablation procedure performed within the prior 2 weeks.
  10. Polymorphic VT or ventricular fibrillation (VF) as the primary clinical heart rhythm, as indicated by 12-lead and/or ICD interrogation.
  11. >3 distinct clinical monomorphic VT morphologies on ICD interrogation since the prior CA, or >5 induced monomorphic VT morphologies during NIPS testing.
  12. Incessant VT that is hemodynamically unstable.
  13. Bundle branch reentry (BBR) VT.
  14. Pregnant and/or breastfeeding. (Patient denial is sufficient for enrollment).
  15. Patients of who:

    • are not on a medically effective means of at the time of screening or do not start a medically effective means of birth control prior to randomization; or
    • do not agree to continue medically effective means of birth control until they have completed their assigned therapy; or
    • do not agree to be on a medically effective means of birth control if they are treated with CRA after their index CA procedure.
  16. Patients enrolled in another clinical study the investigator believes to be in conflict with this clinical investigation.
  17. Patients enrolled or planned to be enrolled in another cardiac radioablation clinical study or registry.
  18. Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Active comparator
    Repeat catheter ablation (CA)

    Procedure: Catheter Ablation (CA)

  • Experimental
    Varian Cardiac Radioablation (CRA)

    Device: Varian Cardiac Radioablation (CRA)

Interventions

  • DeviceVarian Cardiac Radioablation (CRA)

    Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.

  • ProcedureCatheter Ablation (CA)

    Subjects randomized to the CA arm will be treated according to a uniform CA protocol.

06

What researchers measure

Primary outcomes

  1. Co-primary safety endpoint: freedom from treatment-attributed (i.e., probably or definitely related) serious adverse events (SAEs)

    Freedom from treatment-attributed (i.e., probably or definitely related) serious adverse events (SAEs), evaluated from treatment through 12 months post-treatment.

    Time frame: Treatment through 12 months post-treatment

  2. Co-primary efficacy endpoint: Freedom from death, and appropriate ICD shock, and VT storm.

    Freedom from death, and appropriate ICD shock, and VT storm, where death will be counted from randomization through 12 months, and shock and storm will be counted starting after a 30-day period immediately post-randomization and continuing through 12 months post randomization.

    Time frame: Death will be counted from randomization through 12 months, and shock and storm will be counted starting after a 30-day period immediately post-randomization and continuing through 12 months post randomization

Secondary outcomes

  1. Change in quality of life at 6 weeks post treatment:

    Change in quality of life at 6 weeks post treatment measured by the Short Form Health Survey 36 (SF-36) Health Change Question. This item asks the subject to rate their health in general compared to one year ago in a 5-point scale of 1 (much better), 2 (somewhat better), 3 (about the same), 4 (somewhat worse), 5 (much worse).

    Time frame: From baseline through 6 weeks post treatment

  2. VT burden reduction

    VT burden reduction measured as a ≥75% reduction in appropriate ICD therapies (ATP, shock), comparing a 6-month period before randomization and a 6-month period starting after a 30-day period immediately post-randomization.

    Time frame: From 6 months before randomization through to a 6 month period starting after a 30-day period immediately post-randomization

  3. Change in quality of life (Social Functioning) at 6 weeks post treatment

    Change in quality of life (Social Functioning) measured by the Short Form Health Survey 36 (SF-36) Social Functioning item (social activities in past 4 weeks). This item asks the subject to rate how much of the time their physical health or emotional problems interfered with their social activities in the past 4 weeks in a 5-point scale of 1 (All of the time), 2 (Most of the time), 3 (Some of the time), 4 (A little bit of the time), 5 (None of the time).

    Time frame: From baseline through 6 weeks post treatment

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2028, 66 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's planned 66 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion May 2026 → Oct 2028 and completion May 2030 → May 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Mar 13, 2023
StartActual
Apr 21, 2023
Primary completionEst.
Oct 2028was May 2026
CompletionEst.
May 2032was May 2030
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Yale University · New Haven, United States
Oct 30, 2026
Primary completion
May 2026→Oct 2028
Oct 30, 2026
Study completion
May 2030→May 2032
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site added
    Show site
    • Yale University · New Haven, United States
    Primary completion May 2026→Oct 2028
    Study completion May 2030→May 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05765175
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Apr 21, 2023
Primary completion
Oct 2028 (estimated)
Completion
May 2032 (estimated)
Last update
Oct 30, 2026

Study contacts

Claire McCann, PhD
Contact
claire.mccann@varian.com
437.240.4531
David J Harrington
Contact
david.harrington@varian.com
+1 (434) 2422995

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion